Novartis AG
- Country
- π¨πSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
- Conditions
- Hepatitis B
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00124241
Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00121316
- Locations
- π¨π
This study is not being conducted in the United States, Novartis Pharma AG, Switzerland
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 400
- Registration Number
- NCT00121381
- Locations
- πΊπΈ
Pediatric Care Medical Group, Inc., Huntington Beach, California, United States
πΊπΈChildren's Hospital -San Diego, San Diego, California, United States
πΊπΈNational Jewish Medical and Research Center, Denver, Colorado, United States
Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-07-18
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 288
- Registration Number
- NCT00120536
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Quality of Life Study in Adults With Facial Eczema
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00120302
- Locations
- π¬π§
This study is not being conducted in the United States, Novartis Pharmaceuticals UK, Frimley, United Kingdom
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
- Conditions
- Tinea Capitis
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 720
- Registration Number
- NCT00117754
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 70
- Registration Number
- NCT00117377
- Locations
- πΊπΈ
Mount Sinai School of Medicine, New York, New York, United States
πΊπΈNew York University Hospital, New York, New York, United States
πΊπΈVirginia Clinical Research, Inc, Norfolk, Virginia, United States
Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Novartis
- Registration Number
- NCT00115245
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00104442
- Locations
- πΊπΈ
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2004-12-06
- Last Posted Date
- 2006-08-31
- Lead Sponsor
- Novartis
- Target Recruit Count
- 66
- Registration Number
- NCT00098150